Lifespan extension therapy: Ruxolitinib (Trade name: Jakavi), a drug used in the treatment of Myelofibrosis,  prolongs mammalian life span via down regulation of angiotensin II type I receptor (AT1R), 30/August/2017, 12.06 am

Natural product therapy for glucose homeostasis and TIIDM: Geniposide (GP), isolated from Gardenia, increases Pax6 and insulin expression, decreases the levels of glucagon, ghrelin and Somatostatin, reduces metabolic stress, improves insulin sensitivity, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 29/August/2017, 1.05 am
August 28, 2017
Molecular therapy for Myocardial Infarction: Rivaroxaban (Trade name: Xarelto), an anticoagulant drug, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up regulation of PNUTS, 30/August/2017, 12.24 am
August 29, 2017
Show all

Significance of the study:

It has been shown earlier that antagonizing angiotensin II type I receptor (AT1R) expression may prolong mammalian life span. Further, it has been shown that disruption of AT1R (AGTR1) gene results in marked prolongation of mammalian lifespan. 


From research findings to therapeutic opportunity: 

This study suggests, for the first time, that Ruxolitinib (Trade name: Jakavi), by increasing the expression of its target genes,  it may decrease the expression of AT1R.

Figure1. Mechanistic insights into how Ruxolitinib (Trade name: Jakavi) functions as a longevity- promoter. Punicalagin, by increasing the expression of its downstream target genes, down regulates A1TR expression and promotes longevity.

And, thereby, it may: (1) decrease blood pressure; (2) decrease blood sugar levels; (3) inhibit pulmonary fibrosis; (4) enhance bacterial immunity; (5) inhibit myocardial infarction; (6) decelerate ageing process; and (4) extend the lifespan of an individual. Thus, pharmacological formulations encompassing “Ruxolitinib (Trade name: Jakavi) or its analogues, either alone or in combination with other anti-ageing/longevity promoting compounds” may be used to extend the lifespan of an individual (Figures 1-2).

Price 300[easy_payment currency=”USD”]


Details of the research findings: 

Idea Proposed/Formulated byDr L Boominathan Ph.D.  

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How  does Ruxolitinib (Trade name: Jakavi) suppress the expression of  angiotensin II type I receptor (AT1R)? 

Amount: $300

For purchase and payment details, you may reach us at info@genomediscovery.org

#  Research cooperation


References: 

CitationBoominathan, L.,  Lifespan extension therapy: Ruxolitinib (Trade name: Jakavi), a drug used in the treatment of Myelofibrosis,  prolongs mammalian life span via down regulation of angiotensin II type I receptor (AT1R), 30/August/2017, 12.06 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or newbioideas.com/

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.